Join

Compare · PCI vs PPH

PCI vs PPH

Side-by-side comparison of PIMCO Dynamic Credit and Mortgage Income Fund (PCI) and VanEck Vectors Pharmaceutical ETF (PPH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PCI and PPH operate in n/a (n/a), so they compete in similar markets.
  • PCI carries a market cap of $3.14B.
  • Over the past year, PCI is up 1.5% and PPH is up 14.6% - PPH leads by 13.1 points.
PerformancePCI+1.51%PPH+17.51%
2025-08-13+0.00%2026-04-24
MetricPCIPPH
Company
PIMCO Dynamic Credit and Mortgage Income Fund
VanEck Vectors Pharmaceutical ETF
Price
$51.24+0.35%
$100.20-1.02%
Market cap
$3.14B
-
1M return
+0.00%
-2.32%
1Y return
+1.51%
+14.61%
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NYSE
NASDAQ
IPO
2013
n/a
News (4w)
0
0
Recent ratings
0
0
PCI

PIMCO Dynamic Credit and Mortgage Income Fund

PIMCO Dynamic Credit and Mortgage Income Fund is a closed end fixed income mutual fund launched and managed by Allianz Global Investors Fund Management LLC. The fund is co-managed by Pacific Investment Management Company LLC. It invests in fixed income markets across the globe. The fund utilizes a dynamic asset allocation approach and seeks to invest in multiple fixed-income sectors in the global credit markets, including corporate debt, mortgage-related and other asset-backed securities, government and sovereign debt, taxable municipal bonds and other fixed, variable and floating rate income producing securities. It benchmarks the performance of its portfolio against a combined benchmark comprised of 80% Barclays Investment Grade Index and 20% BofA High Yield Index. The fund was formerly known as PIMCO Dynamic Credit Income Fund. PIMCO Dynamic Credit and Mortgage Income Fund was formed on January 31, 2013 and is domiciled in the United States.

PPH

VanEck Vectors Pharmaceutical ETF

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.